Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study.

Abstract

Preclinical models of psychosis propose that hippocampal glutamatergic neuron hyperactivity drives increased striatal dopaminergic activity, which underlies the development of psychotic symptoms. The aim of this study was to examine the relationship between hippocampal glutamate and subcortical dopaminergic function in people at clinical high risk for psychosis, and to assess the association with the development of psychotic symptoms. 1H-MRS was used to measure hippocampal glutamate concentrations, and 18F-DOPA PET was used to measure dopamine synthesis capacity in 70 subjects (51 people at clinical high risk for psychosis and 19 healthy controls). Clinical assessments were undertaken at baseline and follow-up (median 15 months). Striatal dopamine synthesis capacity predicted the worsening of psychotic symptoms at follow-up (r = 0.35; p < 0.05), but not transition to a psychotic disorder (p = 0.22), and was not significantly related to hippocampal glutamate concentration (p = 0.13). There were no differences in either glutamate (p = 0.5) or dopamine (p = 0.5) measures in the total patient group relative to controls. Striatal dopamine synthesis capacity at presentation predicts the subsequent worsening of sub-clinical total and psychotic symptoms, consistent with a role for dopamine in the development of psychotic symptoms, but is not strongly linked to hippocampal glutamate concentrations.

• Authors: Oliver D Howes, Ilaria Bonoldi, Robert A McCutcheon, Matilda Azis, Mathilde Antoniades, Matthijs Bossong, Gemma Modinos, Jesus Perez, James M Stone, Barbara Santangelo, Mattia Veronese, Anthony Grace, Paul Allen, Philip K McGuire
• Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (Neuropsychopharmacology) Vol. 45 Issue 4 Pg. 641-648 (03 2020) ISSN: 1740-634X [Electronic] England
• PMID: 31618752 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Glutamic Acid
• Dopamine

Topics

• Adult
• Case-Control Studies
• Dopamine (metabolism)
• Female
• Follow-Up Studies
• Glutamic Acid (metabolism)
• Humans
• Longitudinal Studies
• Magnetic Resonance Imaging
• Magnetic Resonance Spectroscopy (methods)
• Male
• Multimodal Imaging (methods)
• Positron-Emission Tomography (methods)
• Psychotic Disorders (diagnostic imaging, metabolism)
• Risk Factors
• Treatment Outcome
• Young Adult